A carregar...
Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations
Emicizumab is a factor (F)VIIIa-mimicking bispecific antibody recognizing FIXa and FX molecules. In the phase 1/2 clinical studies, once-weekly subcutaneous administration of emicizumab has shown a favorable safety profile with encouraging efficacy in the patients with hemophilia A (PwHA) irrespecti...
Na minha lista:
| Publicado no: | J Blood Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613000/ https://ncbi.nlm.nih.gov/pubmed/31308776 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S175952 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|